ClinicalTrials.gg
CompletedNCT04621318Updated Nov 28, 2022

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

A Phase 1 interventional study of Denosumab in Healthy, sponsored by Samsung Bioepis Co., Ltd.. Completed at 2 sites in 2 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-28.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
Male
01

Study summary

This study is to compare PK, PD, safety, tolerability, and immunogenicity profiles of SB16, EU sourced Prolia, and US sourced Prolia in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male, aged 28-55 years (inclusive) on the day of signing the .
  2. Have a body weight between 60.0-90.0 kg (inclusive) and a between 20.0-29.9 kg/m2 (inclusive).
  3. Have 12-lead results without abnormal findings confirmed by the Investigator.
  4. Have vital sign results without clinically significant abnormal findings confirmed by the Investigator.
  5. Have physical examination results without clinically significant abnormal findings confirmed by the Investigator.
  6. Male subjects who have not had surgical sterilisation must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of , such as an intra-uterine device, oral contraceptive, injectable progesterone, sub-dermal implant, or tubal ligation unless their partners are infertile (confirmed with written verifications) during the treatment period.
  7. Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
  8. Able to provide written informed consent, which must be obtained prior to any study related procedures being performed.
  9. Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.

Exclusion criteria

Exclusion Criteria:

  1. Have a history and/or current presence of atopic allergy, , or allergic reactions (either spontaneous or following drug administration), also including known or suspected clinically relevant drug hypersensitivity to denosumab or to any of the .
  2. Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric disorder, drug or alcohol abuse, or allergic disease excluding mild asymptomatic seasonal allergies.
  3. Have a history of bone disease or any medical condition that can affect bone metabolism (including osteoporosis, osteogenesis imperfecta, osteomalacia, hyperparathyroidism, hyperthyroidism, hypothyroidism, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Paget's disease of the bone, and malabsorption syndrome).
  4. Have a history of (including lymphoma, leukaemia, and skin cancer).
  5. Have ONJ or risk factors for ONJ such as invasive dental procedures or active periodontal disease within 180 days prior to Randomisation.
  6. Have bone fractures within 180 days prior to Randomisation.
  7. Have a history of serious infection (associated with hospitalisation and/or which required intravenous antibiotics) within 180 days prior to Randomisation.
  8. Have a clinically significant active infection (bacterial, viral, or fungal) including skin infections within 28 days prior to Randomisation.
  9. Have any systemic or local infection, a known risk for developing sepsis.
  10. Have known intolerance to calcium or vitamin D supplements.
  11. Have previously been exposed to denosumab (Prolia®/Xgeva®) and its biosimilar.
  12. Have previously been exposed to a monoclonal antibody or fusion protein within 270 days (other than denosumab) prior to Randomisation and/or there is confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein.
  13. Have previously been exposed to an agent or biological agent (any other than a monoclonal antibody or fusion protein) within 120 days prior to Randomisation.
  14. Have received (s) within 30 days prior to Randomisation or who will require live vaccine(s) during the study period.
  15. Have a personal or family history of prolonged syndrome or Torsade de Pointes, or family history of sudden death.
  16. Have any of the following abnormal laboratory test results:

    1. Albumin-adjusted serum calcium levels below the LLN or above the .
    2. Serum creatinine levels above 1.5 × ULN.
    3. Any other laboratory abnormalities assessed as clinically significant by the Investigator.
  17. Have a positive test result for , antibody, or 1or 2.
  18. Have a history of immunodeficiency.
  19. Have had surgery within 90 days prior to Randomisation, and/or plan to have an operation (including invasive dental procedure) during the study period.
  20. Have a history and/or current presence of an illness (including, but not limited to respiratory symptoms [e.g., difficulty breathing or persistent cough] or low-grade fever) within 14 days prior to Randomisation that is classified as clinically significant by the Investigator.
  21. Have smoked more than 10 cigarettes, 2 cigars, or 2 pipes per day within 90 days prior to Screening.
  22. Have regular consumption of alcoholic beverages that exceeds 14 units per week.
  23. Have a positive urinary drug screening result or alcohol breath test result at Screening or Day -1.
  24. Have taken any prescription medicine or over-the-counter medicines (except paracetamol) that might have an effect on the objectives of the study in the opinion of the Investigator, within 30 days or 10 half-lives of the medication (whichever period is longer) prior to Randomisation. This includes medications such as, but not limited to: Bisphosphonates, parathyroid hormone, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, calcitriol, , fluoride, strontium, or anabolic steroids.
  25. Have donated > 100 mL blood or plasma within 28 days prior to Randomisation.
  26. Have participated in another study with an drug within 60 days prior to Randomisation or are currently participating in or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluation in this clinical study.
  27. Subjects who, in the opinion of the Investigator, are not likely to complete the study for whatever reason.
  28. Subject who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the clinical study.
  29. Vulnerable subjects
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    SB16

    SB16 (proposed denosumab biosimilar)

    Drug: Denosumab

  • Active comparator
    EU Prolia

    EU sourced Prolia (denosumab)

    Drug: Denosumab

  • Active comparator
    US Prolia

    US sourced Prolia (denosumab)

    Drug: Denosumab

Interventions

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from time zero to infinity

    Time frame: Day 1 to Day 197

  2. AUClast

    Area under the concentration-time curve from time zero to the last quantifiable concentration

    Time frame: Day 1 to Day 197

  3. Cmax

    Maximum serum concentration

    Time frame: Day 1 to Day 197

Secondary outcomes

  1. Tmax

    Time to reach Cmax

    Time frame: Day 1 to Day 197

  2. Vz/F

    Apparent volume of distribution during the terminal phase

    Time frame: Day 1 to Day 197

  3. λz

    Terminal rate constant

    Time frame: Day 1 to Day 197

  4. t1/2

    Terminal half-life

    Time frame: Day 1 to Day 197

  5. CL/F

    Apparent clearance

    Time frame: Day 1 to Day 197

  6. %AUCextrap

    Percentage of AUCinf due to extrapolation from Tlast to infinity

    Time frame: Day 1 to Day 197

  7. AUEC for CTX percent inhibition

    Area under the effect curve from time zero to Day 197 for serum CTX percent inhibition

    Time frame: Day 1 to Day 197

  8. Incidence of TEAEs

    Experience at least 1 TEAE

    Time frame: Day 1 to Day 197

  9. Incidence of SAEs

    Experience at least 1 SAE

    Time frame: Day 1 to Day 197

  10. Incidence of ADAs

    Incidence of ADAs to denosumab

    Time frame: Day 1 to Day 197

  11. Incidence of NAbs

    Incidence of NAbs to denosumab

    Time frame: Day 1 to Day 197

07

Study locations

2 sites
  • Biotrial
    Newark, New Jersey 07103, United States
  • Biotrial Rennes
    Rennes, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Nov 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 9, 2020
StartActual
Oct 19, 2020
Primary completionActual
Nov 9, 2022
CompletionActual
Nov 9, 2022
Last update
Nov 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04621318
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Oct 19, 2020
Primary completion
Nov 9, 2022
Completion
Nov 9, 2022
Last update
Nov 28, 2022

Study contacts

Hakim Charfi, MD
principal investigator · Biotrial Rennes

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion